| Name | Title | Contact Details |
|---|---|---|
Drake McCrary |
Vice President of Sales | Profile |
Chris Dumpert |
Director of Marketing | Profile |
Nina Barwick |
Senior Director, Finance | Profile |
Julia Ducayet |
Chief Marketing Officer | Profile |
Sovereign Pharmaceuticals is your ideal CDMO partner for your pharma product development, formulation, fill/finish, packaging & commercial manufacturing needs.
PRA International is a Raleigh, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its proprietary gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.
Auburn Pharmaceutical is a national full line generics wholesaler that purchases all of its products directly from 100+ manufacturers and is licensed across the Continental United States.
Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.